asco@alo33:161350 JSONTXT

{"project":"ASCO_abstracts","denotations":[{"id":"T1","span":{"begin":583,"end":596},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":777,"end":780},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":1299,"end":1308},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":1573,"end":1575},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0007540"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0010446"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0021156"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0011449"}],"text":" Background: Neuroendocrine tumours NETs are a group of heterogeneous neoplasms. Despite advances, detection and quantification of NET activity by imaging remains a challenge, ith no universally accepted imaging standard. We present the first in-man study of 18F-fluoroethyl triazole [Tyr3] octreotate 18F-FET-x3B2;AG TOCA in NET patients to evaluate biodistribution, dosimetry, and safety. Methods:18F-FET-x3B2;AG TOCA as synthesized via the click reaction Iddon L et al, 2011 . Nine patients 6 female , 3 male ere enrolled into study. Eight patients ith sporadic NET and 1 MEN1 syndrome. Mean age 56 yr range 35-73 yr and eight 75.2kg 66.3-91.2 kg . Safety data as collected during and 24 hours post tracer administration. Patients underent hole body PET-CT multi-bed scanning over 4 hours and venous blood samples ere taken at specific intervals to measure 18F radioactivity concentration in blood and plasma. Regions of interest ere dran, to derive individual and mean organ residence times; effective dose ED as calculated ith OLINDA 1.1. Results: All patients tolerated 18F-FET-x3B2;AG TOCA ith no adverse events. Over 60 percent parent tracer as present in plasma at 60 minutes. High tracer uptake as observed in tumours primary and metastases . Physiological uptake as seen in pituitary, salivary, thyroid and spleen, ith lo background uptake in liver, an organ here metastases commonly occur. The organs receiving highest absorbed dose ere gallbladder, spleen, stomach, liver, kidneys and bladder. The calculated ED over all subjects as 0.029mSvMBq SD 0.004 . Conclusions: We present the first in-man study of 18F-FET-x3B2;AG-TOCA. The favourable safety, imaging and dosimetric profile makes it a valuable candidate in staging and management of NETs. Clinical studies in an expanded cohort are ongoing to clinically qualify this agent. Clinical trial information: 2013-003152-20.,J Clin Oncol 34, 2016 suppl; abstr e15645 , 2013-003152-20Publication Only Gastrointestinal Noncolorectal Cancer \n"}